company background image
WINT logo

Windtree Therapeutics NasdaqCM:WINT Stock Report

Last Price

US$0.36

Market Cap

US$2.8m

7D

6.7%

1Y

-94.7%

Updated

28 Feb, 2024

Data

Company Financials +

Windtree Therapeutics, Inc.

NasdaqCM:WINT Stock Report

Market Cap: US$2.8m

WINT Stock Overview

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases.

WINT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Windtree Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Windtree Therapeutics
Historical stock prices
Current Share PriceUS$0.36
52 Week HighUS$18.48
52 Week LowUS$0.28
Beta0.62
1 Month Change-21.90%
3 Month Change-68.35%
1 Year Change-94.72%
3 Year Change-99.83%
5 Year Change-99.94%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Dec 06

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Jul 06

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Jun 09
Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Feb 09
Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Shareholder Returns

WINTUS BiotechsUS Market
7D6.7%4.7%2.1%
1Y-94.7%11.8%26.0%

Return vs Industry: WINT underperformed the US Biotechs industry which returned 10.7% over the past year.

Return vs Market: WINT underperformed the US Market which returned 25.1% over the past year.

Price Volatility

Is WINT's price volatile compared to industry and market?
WINT volatility
WINT Average Weekly Movement11.6%
Biotechs Industry Average Movement11.8%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: WINT's share price has been volatile over the past 3 months.

Volatility Over Time: WINT's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199220Craig Fraserhttps://windtreetx.com

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a scientific collaboration with Chang Gung University for cardiovascular diseases of SERCA2a; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.

Windtree Therapeutics, Inc. Fundamentals Summary

How do Windtree Therapeutics's earnings and revenue compare to its market cap?
WINT fundamental statistics
Market capUS$2.79m
Earnings (TTM)-US$24.83m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
WINT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$24.83m
Earnings-US$24.83m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.92
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio206.7%

How did WINT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.